Panel 1 Whitepaper – Panel 1 Slides Panel 2 Whitepaper – Panel 2 Slides Panel 3 Whitepaper – Panel 3 Slides This year’s Friends Annual Meeting took place on November 15, 2017. The event began with a keynote by FDA Commissioner Dr. Scott Gottlieb. During his remarks, Dr. Gottlieb reiterated previous commitments for the…
Friends of Cancer Research with Alexandria Real Estate Equities, Inc. Co-Host: A Blueprint for Breakthrough – Charting the Course for Precision Medicine Click HERE to access the finalized meeting whitepaper. On Wednesday, September 13, 2017, Friends of Cancer Research (Friends) with Alexandria Real Estate Equities Inc. co-hosted the 6th annual Blueprint for Breakthroughs forum. This…
October 4, 2017 The Hay-Adams 800 16th St NW, Washington, DC 20006 On October 4, 2017, Friends of Cancer Research (Friends) hosted the 21st Annual Cancer Leadership Awards Reception. The yearly event brings together leaders in government, advocacy, industry, and science to celebrate partnerships and innovations that benefit patients. To mark the five-year anniversary of…
Friends of Cancer Research Vice President – Public Affairs, Ryan Hohman, shares why he is passionate about the Friends mission of bringing life-saving treatments to patients in the fastest and safest way possible in the latest installment of “My Story.” From a young age, Ryan has been witness to how cancer impacts families and saw what he…
In his first speech to Congress last February, President Trump revived a common misconception about drug regulation. The president’s comments reflect a perennial critique of the FDA, that the agency’s drug regulations impede timely access to new medicines. A few years ago, Friends of Cancer Research (Friends) explored whether these claims were true about cancer…
This is Data Driven, a new series that explore our nation’s health agencies’ publicly available data. This data, which is comprised of searchable online databases and files, presents a unique opportunity to analyze information on broad health care topics. We thought it would be interesting to explore data from agencies whose work most closely…
In 2012, the Breakthrough Therapy Designation was signed into law. Four years later, Friends of Cancer Research (Friends) continues to steward the program that the organization developed by working closely with FDA and other stakeholders to ensure the program is as efficient and effective as possible. As part of this stewardship, Friends hosted a Senate briefing…
Congress Must Pass 21st Century Cures Act Now This is an incredibly exciting time in biomedical research. New discoveries are announced almost every week that bring us closer to managing cancer and other life-threatening diseases. We are attacking these illnesses at the molecular and genetic levels. In cancer, for example, scientists have gone beyond treating…
It’s been a busy spring for drug development. We’ve had leadership changes at FDA, legislative pushes in Congress, and a host of conferences and meetings to present and advance ideas from the cutting edge of science and policy. It’s a lot of keep up with. Here are the biggest stories from the last few months.…
This Friday, the U.S. House will vote on the 21st Century Cures Act. The Act creates a cohesive, efficient, effective, and patient-centered path to cures. The 21st Century Cures Act, a substantial piece of legislation that touches on all aspects of medical innovation – from basic research to regulation, from biomarkers to patient data –…
